Compositions and methods to treat recurrent medical conditions

Details Compositions and methods to treat recurrent medical conditions Compositions and methods to treat recurrent medical conditions

2004-12-29

2010-12-07

Hui, San-ming (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07846913

ABSTRACT:
The invention describes methods and compositions for alleviating recurrent medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction. Representative afflictions include insomnia, erectile dysfunction, female sexual dysfunction, neuropathic pain, attention deficit disorder, and depression.

REFERENCES:
patent: 5061721 (1991-10-01), Cordi
patent: 5086072 (1992-02-01), Trullas
patent: 5260324 (1993-11-01), Cordi
patent: 5428069 (1995-06-01), Skolnick
patent: 5523323 (1996-06-01), MacCecchini
patent: 6133281 (2000-10-01), Gonzalez-Cadavid et al.
patent: 6228875 (2001-05-01), Tsai
patent: 6333357 (2001-12-01), Elg
patent: 6355681 (2002-03-01), Javitt
patent: 6420351 (2002-07-01), Tsai
patent: 6667297 (2003-12-01), Tsai
patent: 2001/0053780 (2001-12-01), Whitaker et al.
patent: 2002/0146471 (2002-10-01), Wuh et al.
patent: 2004/0208923 (2004-10-01), Davis et al.
patent: 2005/0096396 (2005-05-01), Davis
patent: WO-02078629 (2002-10-01), None
Nurnberg (Depression, Antidepressant therapies, and Erectile Dysfunction: Clinical Trial of Sildenafil Citrate (Viagra®) in Treated and Untreated Patients with Depression, Urology 60 (Suppl 2B); pp. 58-66, 2002).
Papp (Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression, European Journal of Pharmacology 316 (1996) pp. 145-151).
Birk, “Pharmacotherapy for Performance Anxiety Disorders . . . ”, Journal of Clinical Psychology, (2004), vol. 60(8), p. 867-879.
Ressler, “Cognitive Enhancers as Adjuncts to Psychotherapy”, Archives of General Psychiatry, (2004); vol. 61, p. 1136-1144.
Mothet, “D-Serine is an endogenous ligand for the glycine site . . . ”, Proc. Natl. Acad. Sci. USA., (2000), vol. 97(9), p. 4926-4931.
Van Berckel, “Behavioral and Neuroendocrine Effects of the Partial NMDA . . . ”, Neuropsychopharmology, (1997), vol. 16(5), p. 317-324.
Wager, “Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain”, Science, (2004), vol. 303, p. 1162-1167.
Yamakura, “Subunit- and Site-Specific Pharmacology of the NMDA Receptor Channel”, Progess in Neurobiology, (1999), vol. 59, p. 279-298.
Boje, “Desensitization of the NMDA Receptor Complex by Glycinergic Ligands . . . ”, Brain Research, (1993), vol. 603(2), p. 207-214.
Walker, “Facilitation of Conditioned Fear Extinction by Systemic Administration . . . ”, The Journal of Neuroscience, (2002), vol. 22, p. 2343-2351.
Heresco-Levy, “Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics . . . ”, Am. J. Psychiatry, (2002), vol. 159(3), p. 480-482.

Affiliated with

Also associated with

Rating

Compositions and methods to treat recurrent medical conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods to treat recurrent medical conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods to treat recurrent medical conditions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4224381